321 related articles for article (PubMed ID: 30735815)
1. Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment.
Zhao X; Kallakury B; Chahine JJ; Hartmann D; Zhang Y; Chen Y; Zhang H; Zhang B; Wang C; Giaccone G
J Thorac Oncol; 2019 May; 14(5):914-923. PubMed ID: 30735815
[TBL] [Abstract][Full Text] [Related]
2. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
4. Distribution characteristics and prognosis of tumor-infiltrating lymphocytes in the brain metastases of small cell lung cancer: a retrospective cohort study.
Qian H; Pang J; Wan C; Mei X; Liao J; Wang B; Milano MT; Suwinski R; Inno A; Du Y
Transl Cancer Res; 2024 May; 13(5):2509-2517. PubMed ID: 38881925
[TBL] [Abstract][Full Text] [Related]
5. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
[TBL] [Abstract][Full Text] [Related]
6. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
7. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
[TBL] [Abstract][Full Text] [Related]
8. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
10. CD3, CD8, IFN-Ī³, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.
Fu M; Feng C; Wang J; Guo C; Wang Y; Gao R; Wang J; Zhu Q; Zhang X; Qi J; Zhang Y; Bian Y; Wang Z; Fang Y; Cao L; Hong B; Wang H
Clin Exp Med; 2024 May; 24(1):99. PubMed ID: 38748269
[TBL] [Abstract][Full Text] [Related]
11. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
[TBL] [Abstract][Full Text] [Related]
12. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.
Iams WT; Shiuan E; Meador CB; Roth M; Bordeaux J; Vaupel C; Boyd KL; Summitt IB; Wang LL; Schneider JT; Warner JL; Zhao Z; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1970-1981. PubMed ID: 31201935
[TBL] [Abstract][Full Text] [Related]
13. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the ResponseĀ of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer.
Sun C; Zhang L; Zhang W; Liu Y; Chen B; Zhao S; Li W; Wang L; Ye L; Jia K; Wang H; Wu C; He Y; Zhou C
Onco Targets Ther; 2020; 13():6475-6483. PubMed ID: 32753888
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
17. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
18. Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery.
Liu L; Wei J; Teng F; Zhu Y; Xing P; Zhang J; Guo Y; Dong J; Ying J; Li J; Yang L
Hum Pathol; 2021 Feb; 108():84-92. PubMed ID: 33245986
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
20. Role of pulmonary resection in the diagnosis and treatment of limited-stage small cell lung cancer: revision of clinical diagnosis based on findings of resected specimen and its influence on survival.
Iwata T; Nishiyama N; Nagano K; Izumi N; Mizuguchi S; Tsukioka T; Morita R; Chung K; Hanada S; Inoue K
Gen Thorac Cardiovasc Surg; 2012 Jan; 60(1):43-52. PubMed ID: 22237738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
